These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 16565897)

  • 21. A patient with ankylosing spondylitis who developed infliximab-induced lupus and treated with etanercept.
    Akgül Ö; Kılıç G; Kılıç E; Cüce İ; Özgöçmen S
    Rheumatol Int; 2014 Mar; 34(3):443-4. PubMed ID: 23263496
    [No Abstract]   [Full Text] [Related]  

  • 22. Successful treatment of a mycophenolate mofetil-refractory proliferative lupus nephritis with Belimumab in a 19-year-old woman.
    Fließer EE; Korsten P; Koziolek MJ; Niewold TB; Patschan D; Müller GA; Patschan SA
    Lupus; 2013 Dec; 22(14):1523-5. PubMed ID: 24014569
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Infliximab: a new treatment for rheumatoid arthritis.
    Emery P
    Hosp Med; 2001 Mar; 62(3):150-2. PubMed ID: 11291464
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab in Takayasu arteritis: a safe alternative?
    Karageorgaki ZT; Mavragani CP; Papathanasiou MA; Skopouli FN
    Clin Rheumatol; 2007 Jun; 26(6):984-7. PubMed ID: 16633710
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combination therapy of mycophenolate mofetil and tacrolimus in lupus nephritis.
    Lanata CM; Mahmood T; Fine DM; Petri M
    Lupus; 2010 Jul; 19(8):935-40. PubMed ID: 20388722
    [TBL] [Abstract][Full Text] [Related]  

  • 26. How does infliximab work in rheumatoid arthritis?
    Maini RN; Feldmann M
    Arthritis Res; 2002; 4 Suppl 2(Suppl 2):S22-8. PubMed ID: 12110154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of tumor necrosis factor-alpha inhibition with inflixiMAB in cancer therapy and hematopoietic stem cell transplantation.
    Couriel DR; Hicks K; Giralt S; Champlin RE
    Curr Opin Oncol; 2000 Nov; 12(6):582-7. PubMed ID: 11085458
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Is mycophenolate mofetil superior to pulse intravenous cyclophosphamide for induction therapy of proliferative lupus nephritis in Egyptian patients?
    El-Shafey EM; Abdou SH; Shareef MM
    Clin Exp Nephrol; 2010 Jun; 14(3):214-21. PubMed ID: 20169461
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Lupusnephritis].
    Haubitz M
    Z Rheumatol; 2012 Dec; 71(10):875-84; quiz 885-6. PubMed ID: 23202997
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multitarget therapy of mycophenolate mofetil and cyclosporine A for induction treatment of refractory lupus nephritis.
    Jesus D; Rodrigues M; da Silva JAP; Inês L
    Lupus; 2018 Jul; 27(8):1358-1362. PubMed ID: 29448882
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long-term outcomes of lupus nephritis treated with regimens based on cyclophosphamide and mycophenolate mofetil.
    Prasad N; Kurian J; Agarwal V; Bhadauria D; Behera M; Yacha M; Kushwaha R; Agrawal V; Jain M; Gupta A
    Lupus; 2020 Jul; 29(8):845-853. PubMed ID: 32437258
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Belimumab and low-doses of mycophenolate mofetil as induction therapy of class IV lupus nephritis: case series and literature review.
    Margiotta DPE; Basta F; Batani V; Afeltra A
    BMC Nephrol; 2018 Mar; 19(1):54. PubMed ID: 29514612
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group.
    Maini R; St Clair EW; Breedveld F; Furst D; Kalden J; Weisman M; Smolen J; Emery P; Harriman G; Feldmann M; Lipsky P
    Lancet; 1999 Dec; 354(9194):1932-9. PubMed ID: 10622295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rituximab and mycophenolate mofetil for relapsing proliferative lupus nephritis: a long-term prospective study.
    Boletis JN; Marinaki S; Skalioti C; Lionaki SS; Iniotaki A; Sfikakis PP
    Nephrol Dial Transplant; 2009 Jul; 24(7):2157-60. PubMed ID: 19179411
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Towards new avenues in the management of lupus glomerulonephritis.
    Mok CC
    Nat Rev Rheumatol; 2016 Apr; 12(4):221-34. PubMed ID: 26729459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Successful treatment of refractory lupus-associated haemophagocytic lymphohistiocytosis with infliximab.
    Ideguchi H; Ohno S; Takase K; Hattori H; Kirino Y; Takeno M; Ishigatsubo Y
    Rheumatology (Oxford); 2007 Oct; 46(10):1621-2. PubMed ID: 17726035
    [No Abstract]   [Full Text] [Related]  

  • 37. Remission and long-term outcomes of proliferative lupus nephritis: retrospective study of 96 patients from Saudi Arabia.
    Almalki AH; Alrowaie FA; Alhozali HM; Almalki NK; Alsubei AI; Alturki MS; Sadagah LF
    Lupus; 2019 Aug; 28(9):1082-1090. PubMed ID: 31296138
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy and safety of infliximab in active SLE: a pilot study.
    Uppal SS; Hayat SJ; Raghupathy R
    Lupus; 2009 Jul; 18(8):690-7. PubMed ID: 19502264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of standard of care treatment with a low steroid and mycophenolate mofetil regimen for lupus nephritis in the ALMS and AURA studies.
    Dall'Era M; Solomons N; Federico R; Truman M
    Lupus; 2019 Apr; 28(5):591-596. PubMed ID: 31066646
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Combination therapy of the chimeric monoclonal anti-tumor necrosis factor alpha antibody (infliximab) with methotrexate in patients with rheumatoid arthritis.
    Antoni C; Kalden JR
    Clin Exp Rheumatol; 1999; 17(6 Suppl 18):S73-7. PubMed ID: 10589362
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.